KPF
BCTX

K2 Principal Fund’s Briacell Therapeutics BCTX Stock Holding History

K2 Principal Fund’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-166
Closed -$156K – 229
2023
Q3 		$156K Buy
+166
New +$162K 0.03% 140

Other funds holding BCTX

LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KJHP
K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
OBWG
Onyx Bridge Wealth Group Tarrytown, New York $1.11B AUM 24.65% 1-Year Est. Return

K2 Principal Fund's BCTX Position: Q4 2023 in Review

K2 Principal Fund sold out of Briacell Therapeutics (BCTX) in Q4 2023, closing a stake of 166 shares — an estimated $156K sold.

K2 Principal Fund first reported a position in BCTX in Q3 2023 and held it in 1 quarter. The position peaked at $156K in Q3 2023. 23 funds tracked by Wall St. Rank hold BCTX as of Q4 2023.

  • K2 Principal Fund reported no remaining Briacell Therapeutics position as of Q4 2023 after selling out during the quarter.
  • K2 Principal Fund sold 166 Briacell Therapeutics shares in Q4 2023, an estimated $156K.
  • K2 Principal Fund first reported a position in Briacell Therapeutics in Q3 2023 and held it in 1 quarter.
  • K2 Principal Fund's Briacell Therapeutics position peaked at $156K in Q3 2023.
  • 23 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q4 2023.

Based on K2 Principal Fund's 13F filing for Q4 2023, filed 14 Feb 2024.